Medical treatment of uterine myoma with long-acting gonadotropin-releasing hormone agonist prior to myomectomy.
A less bulky uterine myoma is technically easier to deal with during surgery. Recently gonadotropin-releasing hormone agonists (GnRH-a) have been used for the purpose of medical hypophysectomy, thereby reducing the size of uterine myomas. Ten premenopausal women with infertility and intramural-submucous myoma manifesting with menorrhagia and obstruction of the tubal ostia were recruited for this study. A long-acting depot GnRH-a, Decapeptyl, was given intramuscularly every four weeks for three months as an adjunct prior to myomectomy. Luteinizing hormone, follicular stimulating hormone and estradiol declined to the menopausal range following treatment. The size of the myoma decreased to a mean of 32.3 +/- 13.3% of the original volume. Myomectomy was performed in eight patients at the end of the study. Remarkably little blood loss was observed during the surgery. All of the patients had their uteri preserved, and six out of eight patients achieved pregnancy within 12 months after surgery. Our results indicate that monthly administration of long-acting GnRH-a significantly reduces the myoma volume and makes myomectomy technically easier to perform with the possibility of reduced complication rates and better preservation of future fertility.
Liu
C H
CH
Department of Obstetrics and Gynecology, National Cheng Kung University Medical College, Tainan, Taiwan, R.O.C.
Lin
Y S
YS
Lin
C C
CC
Tzeng
C C
CC
Chou
C Y
CY
D000328:Adult; D003131:Combined Modality Therapy; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D007889:Leiomyoma / Q000188:drug therapy* / Q000601:surgery; D008875:Middle Aged; D017329:Triptorelin Pamoate / Q000008:administration & dosage / Q000627:therapeutic use*; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000601:surgery; D014599:Uterus / Q000601:surgery*
D003692:Delayed-Action Preparations; D017329:Triptorelin Pamoate